Hier finden Sie wissenschaftliche Publikationen aus den Fraunhofer-Instituten.

CAR-expressing natural killer cells for cancer retargeting

: Klöß, Stephan; Kretschmer, Anna; Stahl, Lilly; Fricke, Stephan; Koehl, Ulrike


Transfusion medicine and hemotherapy 46 (2019), Nr.1, S.4-13
ISSN: 1660-3796
ISSN: 1660-3818
Fraunhofer IZI ()
chimeric antigen receptor; natural killer cell; NK-92; CAR-NK cell; solid tumour; haematological malignancies

Since the approval in 2017 and the outstanding success of Kymriah® and Yescarta®, the number of clinical trials investigating the safety and efficacy of chimeric antigen receptor-modified autologous T cells has been constantly rising. Currently, more than 200 clinical trials are listed on In contrast to CAR-T cells, natural killer (NK) cells can be used from allogeneic donors as an “off the shelf product” and provide alternative candidates for cancer retargeting. This review summarises preclinical results of CAR-engineered NK cells using both primary human NK cells and the cell line NK-92, and provides an overview about the first clinical CAR-NK cell studies targeting haematological malignancies and solid tumours, respectively.